Breakthrough Recognition: Atossa’s (Z)-Endoxifen Earns FDA Rare Pediatric Disease Designation for McCune-Albright Syndrome
Atossa Therapeutics Inc. has achieved a significant regulatory milestone with the U.S. Food and Drug Administration's grant of Rare Pediatric Disease (RPD) designation to (Z)-endoxifen for treating McCune-Albright syndrome (MAS)…
Continue Reading
Breakthrough Recognition: Atossa’s (Z)-Endoxifen Earns FDA Rare Pediatric Disease Designation for McCune-Albright Syndrome
